These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36579458)

  • 1. Proof-of-concept randomized controlled trial of single-session nitrous oxide treatment for refractory bipolar depression: Focus on cerebrovascular target engagement.
    Kim WSH; Dimick MK; Omrin D; Mitchell RHB; Riegert D; Levitt A; Schaffer A; Belo S; Iazzetta J; Detzler G; Choi M; Choi S; Herrmann N; McIntyre RS; MacIntosh BJ; Orser BA; Goldstein BI
    Bipolar Disord; 2023 May; 25(3):221-232. PubMed ID: 36579458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrous oxide as a putative novel dual-mechanism treatment for bipolar depression: Proof-of-concept study design and methodology.
    Dimick MK; Omrin D; MacIntosh BJ; Mitchell RHB; Riegert D; Levitt A; Schaffer A; Belo S; Iazzetta J; Detzler G; Choi M; Choi S; Orser BA; Goldstein BI
    Contemp Clin Trials Commun; 2020 Sep; 19():100600. PubMed ID: 32637725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Mood Improvement with Laughing Gas Exposure (SMILE): Study protocol for a randomized placebo-controlled pilot trial of nitrous oxide for treatment-resistant depression.
    Ladha KS; Lee J; Mattina GF; Pazmino-Canizares J; Wijeysundera DN; Gholamali Nezhad F; Philip K; Tassone VK; Adamsahib F; Bhat V;
    PLoS One; 2024; 19(1):e0297330. PubMed ID: 38241247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial.
    Nagele P; Duma A; Kopec M; Gebara MA; Parsoei A; Walker M; Janski A; Panagopoulos VN; Cristancho P; Miller JP; Zorumski CF; Conway CR
    Biol Psychiatry; 2015 Jul; 78(1):10-18. PubMed ID: 25577164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.
    McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB
    JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.
    Savitz JB; Teague TK; Misaki M; Macaluso M; Wurfel BE; Meyer M; Drevets D; Yates W; Gleason O; Drevets WC; Preskorn SH
    Transl Psychiatry; 2018 Jan; 8(1):27. PubMed ID: 29362444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontocingulate cerebral blood flow and cerebrovascular reactivity associated with antidepressant response in late-life depression.
    Abi Zeid Daou M; Boyd BD; Donahue MJ; Albert K; Taylor WD
    J Affect Disord; 2017 Jun; 215():103-110. PubMed ID: 28324779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression.
    Toniolo RA; Silva M; Fernandes FBF; Amaral JAMS; Dias RDS; Lafer B
    J Neural Transm (Vienna); 2018 Feb; 125(2):247-257. PubMed ID: 29177955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
    Feder A; Costi S; Rutter SB; Collins AB; Govindarajulu U; Jha MK; Horn SR; Kautz M; Corniquel M; Collins KA; Bevilacqua L; Glasgow AM; Brallier J; Pietrzak RH; Murrough JW; Charney DS
    Am J Psychiatry; 2021 Feb; 178(2):193-202. PubMed ID: 33397139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
    Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
    Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral blood flow in bipolar disorder: A systematic review.
    Toma S; MacIntosh BJ; Swardfager W; Goldstein BI
    J Affect Disord; 2018 Dec; 241():505-513. PubMed ID: 30149339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional cerebral blood flow in late-life depression: arterial spin labelling magnetic resonance study.
    Colloby SJ; Firbank MJ; He J; Thomas AJ; Vasudev A; Parry SW; O'Brien JT
    Br J Psychiatry; 2012 Feb; 200(2):150-5. PubMed ID: 22194184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression.
    Nagele P; Palanca BJ; Gott B; Brown F; Barnes L; Nguyen T; Xiong W; Salloum NC; Espejo GD; Lessov-Schlaggar CN; Jain N; Cheng WWL; Komen H; Yee B; Bolzenius JD; Janski A; Gibbons R; Zorumski CF; Conway CR
    Sci Transl Med; 2021 Jun; 13(597):. PubMed ID: 34108247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrous Oxide: an emerging novel treatment for treatment-resistant depression.
    Quach DF; de Leon VC; Conway CR
    J Neurol Sci; 2022 Mar; 434():120092. PubMed ID: 34953347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
    McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
    J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.